CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013 and became CFO the following year.
Liver disease company Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) promoted Jason Campagna to CMO from SVP and NASH program leader. He succeeds David Shapiro, who retired in May.
Nektar Therapeutics (NASDAQ:NKTR) hired John Northcott as SVP and chief commercial officer, a newly created position. Northcott served as chief commercial officer of AbbVie Inc. (NYSE:ABBV) unit Pharmacyclics Inc. in 2015-19.
Cellular metabolism company Agios Pharmaceuticals Inc. (NASDAQ:AGIO) hired Bruce Car as CSO, effective Jan. 6. Car succeeds Scott Biller, who will retire at year end but remain a strategic adviser through 2020. Car is interim head of drug discovery at Bristol-Myers Squibb Co. (NYSE:BMY); he has been with the pharma and its legacy companies for 25 years.
Lawrence Mehren will retire as CEO of Accelerate Diagnostics Inc. (NASDAQ:AXDX) while remaining with the infectious disease diagnostic company as an adviser through 2021. COO Jack Phillips will become CEO Feb. 1.
The Association of the British Pharmaceutical Industry (ABPI) promoted Richard Torbett to CEO from executive director of economic, health and commercial policy, effective Jan. 1. He succeeds CEO Mike Thompson, who will retire from the trade group at year end.
Amphivena Therapeutics Inc. said Curtis Ruegg will succeed Jeanmarie Guenot as president and CEO. Guenot, who is a founder of the immuno-oncology company, will remain as an adviser. Ruegg was president and CEO of Parvus Therapeutics Inc.
Repare Therapeutics Inc. hired Steve Forte as EVP and CFO. Forte was CFO of Clementia Pharmaceuticals, which was acquired by Ipsen Group (Euronext:IPN; Pink:IPSEY) in April. The synthetic lethality company also said Samarth Kulkarni will join its board; Kulkarni is CEO of CRISPR Therapeutics AG (NASDAQ:CRSP) (see “Repare Readies For Clinic With Cowen-led $82M B Round”).
Gene therapy and gene editing company Homology Medicines Inc. (NASDAQ:FIXX) hired Gabriel Cohn as CMO. Cohn was VP of clinical development at Avrobio Inc. (NASDAQ:AVRO).
Neurodegeneration company Caraway Therapeutics (formerly Rheostat Therapeutics) hired Martin Williams as CEO and appointed Cristina Csimma chair. Williams was executive chairman at Yuma Therapeutics Corp.; Csimma was executive chair at Exonics Therapeutics Inc., which Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) acquired. RA Capital’s Joshua Resnick was chairman and interim CEO of Caraway; he co-founded the company and will remain on the board.
Renal disease play Tricida Inc. (NASDAQ:TCDA) hired Elizabeth Faust as SVP of medical affairs. She was VP of medical affairs of the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD).
Revance Therapeutics Inc. (NASDAQ:RVNC) promoted Dustin Sjuts to chief commercial officer, aesthetics and therapeutics. He was the neurology company’s head of commercial, aesthetics and therapeutics.
Metabolic disease company Poxel S.A. (Euronext:POXEL) announced CMO and EVP Late Development and Medical Affairs Christophe Arbet-Engels resigned to pursue other opportunities, and hired Quentin Durand as chief legal officer. Durand was a lawyer at Dechert LLP.
Orexo AB (SSE:ORX), which is developing therapies to treat addiction, hired Dennis Urbaniak as EVP of digital health. He was chief digital officer at Havas Health & You subsidiary of Havas Creative Group and CEO of its U.S.-based Havas Health Plus agency.
Xenikos B.V. hired Stanley Musial as CFO and CBO. Musial served as CFO of EryDel S.p.A., Egalet Corp., Strategic Diagnostics Inc. and Prism Pharmaceuticals Inc., which Baxter International Inc. (NYSE:BAX) acquired.
Antibody company Alligator Bioscience AB (SSE:ATORX) hired Malin Carlsson as COO. Carlsson was VP, head of translational medicine at Ferring Pharmaceuticals A/S.